Identifying and Validating Biomarkers to Develop Truly Disease Modifying Therapeutics for Alzheimer’s Disease
The Biomarkers for Alzheimer’s Disease Summit is the industry’s only digital forum dedicated to solving the challenges of developing clinically validated biomarkers for the earlier detection and diagnosis of Alzheimer’s Disease that are predictive of outcome measures and accurately reflect a therapeutic effect on target engagement.
With an emphasis on looking beyond amyloid and tau and diversifying the biomarker landscape, this industry-defining meeting delves into blood-based biomarkers, neuroinflammatory markers, NFL, microglial activation, exosomes and CSF synaptic biomarkers. Through open reflections and sharing competitive knowledge, this meeting will enable drug developers to scale the hurdles preventing the identification and validation of biomarkers to accelerate the development of disease modifying therapeutics for Alzheimer’s.
The Biomarkers for Alzheimer’s Disease Summit is your opportunity to discuss in-depth the cutting-edge advances in biomarker science, convey lessons learned and network to build long lasting partnerships.
Join us online this July when your community comes together for the first time!
World-Class Speaker Faculty Includes:
Senior Director, Discovery & Clinical Biomarkers
Founder & CEO
Professor of Neurology, Harvard Medical School, Translational Neurology Head
MGH Interdisciplinary Brain Center
Vice President of Translational Biology
Senior Vice President
Research Programs Michael J Fox Foundation